Screener
Veracyte VCYT Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 91,994 | 96,443 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 125,000,000 shares authorized, 79,791,856 and 79,359,005 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 80 | 79 |
| Additional paid-in capital | 1,701,470 | 1,695,339 |
| Accumulated deficit | (348,923) | (377,630) |
| Accumulated other comprehensive loss | (8,221) | (8,212) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's preferred stock, shares authorized?
- Veracyte (VCYT) reported preferred stock, shares authorized of $5M in Q1 2026.
- How has Veracyte's preferred stock, shares authorized changed year-over-year?
- Veracyte's preferred stock, shares authorized decreased by 0.0% year-over-year, from $5M to $5M.
- What is the long-term trend for Veracyte's preferred stock, shares authorized?
- Over 5 years (2020 to 2025), Veracyte's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $5M to $5M.
Ask your AI about Veracyte's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude